Department of Radiation Oncology, Royal Prince Alfred Hospital, Sydney; Sydney Medical School, The University of Sydney, Sydney.
Department of Orthopaedic Surgery, Royal Prince Alfred Hospital, Sydney.
Ann Oncol. 2013 Oct;24(10):2676-2680. doi: 10.1093/annonc/mdt252. Epub 2013 Jul 12.
En bloc resection, extracorporeal irradiation (ECI) and reimplantation have been used selectively at our centers as part of limb preservation surgery of malignant bone tumors since 1996. We report the long-term oncological outcomes.
One hundred one patients were treated with ECI at two Australian centers between 1996 and 2011. A single dose of 50 Gy was delivered to the resected bone segments. The irradiated bones were reimplanted immediately as a biological graft. Patients were treated with chemotherapy as per standard protocol. The three main histological diagnoses were Ewing's sarcoma (35), osteosarcoma (37) and chondrosarcoma (20). There were nine patients with a range of different histologies.
There was one local recurrence (2.86%) in Ewing's sarcoma and the 5-year cumulative overall survival was 81.9%. There was no local recurrence in osteosarcoma and five distant recurrences. The 5-year cumulative overall survival was 85.7%. The local recurrence rate was 20% (4 of 20) in chondrosarcoma, and the 5-year cumulative overall survival was 80.8%. Limb preservation was achieved in 97 patients. For the 64 patients with disease in the pelvis or lower limb, 53 (82.3%) could walk without aids at the time of last follow-up.
This large series of ECI shows an excellent long-term local control. It is a good alternative reconstruction method in selected patients. The overall survival is comparable to other published series.
自 1996 年以来,我们中心选择性地采用整块切除、体外照射(ECI)和再植入作为恶性骨肿瘤保肢手术的一部分。我们报告长期肿瘤学结果。
1996 年至 2011 年,在澳大利亚的两个中心,101 名患者接受了 ECI 治疗。对切除的骨段给予单次 50Gy 的剂量。照射后的骨头立即作为生物移植物再植入。根据标准方案对患者进行化疗。三种主要的组织学诊断为尤因肉瘤(35 例)、骨肉瘤(37 例)和软骨肉瘤(20 例)。还有 9 例患者的组织学类型不同。
在尤因肉瘤中仅有 1 例局部复发(2.86%),5 年总生存率为 81.9%。骨肉瘤无局部复发,5 例远处复发,5 年总生存率为 85.7%。软骨肉瘤局部复发率为 20%(20 例中有 4 例),5 年总生存率为 80.8%。97 名患者实现了肢体保留。对于 64 名患有骨盆或下肢疾病的患者,53 名(82.3%)在最后一次随访时无需辅助即可行走。
这项大型 ECI 系列研究显示出优异的长期局部控制效果。它是一种在选择患者中很好的替代重建方法。总生存率与其他已发表的系列相似。